Meeting

We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. BIOLOGICS WORLD TAIWAN is Taiwan’s premier annual biotherapeutics industry event, organized by the international […]

Website link: https://news.gbimonthly.com/tw/article/show.php?num=75729&page=1

The annual Taiwan Healthcare+ Expo will be held from December 5 to 8, 2024, at Hall 1 of the Nangang Exhibition Center. We are honored to be invited to showcase our booth in the InnoZone Innovation Technology Pavilion. You’re welcome to visit us and learn about our latest developments!

Dr. Kun-Po Li, the director of business development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. Dr. Li will unravel the innovations behind our cutting-edge therapeutic peptides and ADC platform, highlighting the distinctive “Multi-Arm Linkers.”

Dr. Tse Wen Chang, Chairman and CEO of Immunwork, and Dr. Art Hsing-Mao Chu, CEO of T-E Meds, have been invited to World ADC Asia 2024 in Korea. They will share updates on our innovative tech platforms and drug candidates, with a special focus on our ADC technologies. Dr. Chu will present “Exploring ADCs With

Our Chairman, Dr. Tse-Wen Chang and VP of R&D, Dr. Hsing-Mao Chu are honored speakers at the prestigious J.P. Morgan Healthcare Conference on Februry 21-22, 2024.  Dr. Chang and Dr. Chu will share company updates, provide invaluable perspectives, and introduce revolutionary tech platforms and drug candidates. 

Dr. Hsing-Mao Chu, CEO at T-E Meds, will be presenting at the prestigious World ADC conference in San Diego on October 16th (Monday) from 4:30 PM to 5:00 PM. He will unveil our groundbreaking joint technology of “Drug Bundles” and “Glycan Modification” in the applications of ADCs. He will also show how this innovative approach enables precise site-specific

Immunwork is thrilled to announce its participation in the upcoming BIO Asia-Taiwan conference. Join us on July 28th as Dr. Kun-Po Li delivers a captivating company presentation.

T-E Meds has been selected as a finalist for the Start-up Stadium picking competition in the BIO international convention.  T-E Meds stand out through its innovative “Multi-Arm Linker” technology platform. This technology can be utalized to design and create novel ADC/ARC drugs to improve the efficacy and safety. T-E Meds was also selected as an

Dr. Hsing-Mao Chu, VP of R&D at Immunwork is speaking at the 2nd Next-Generation Conjugates Summit in Boston next week. Dr. Chu will introduce our innovative antibody-radionuclide conjugate (ARC) technology platform and its application in pancreatic cancer diagnosis/treatment.Join us at this exciting conference!